Products for Research Use Only

Ivacaftor-d4

CAT: 0804-HY-13017S3-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13017S3-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ivacaftor-d4 (VX-770-d4) is the deuterium labeled-Ivacaftor. Ivacaftor is a potent and orally active CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively[1].
Product Name Alternative
VX-770-d4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CFTR
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Purity
97.32
Solubility
10 mM in DMSO|DMSO : 50mg/mL (ultrasonic)
Smiles
O=C(C1=CNC2=C(C1=O)C([2H])=C([2H])C([2H])=C2[2H])NC3=CC(O)=C(C(C)(C)C)C=C3C(C)(C)C
Molecular Formula
C24H24D4N2O3
Molecular Weight
396.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Delaunay JL, et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770) . Hepatology. 2017 Feb;65 (2) :560-570|[2]Mutyam V, et al. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros. 2017 Jan;16 (1) :24-29|[3]Hadida S, et al. Discovery of N- (2,4-di-tert-butyl-5-hydroxyphenyl) -4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. J Med Chem. 2014 Dec 11;57 (23) :9776-9|[4]Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106 (44) :18825-30.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported